Endpoint
Psoriasis Area and Severity Index (PASI) score
CAT:outcome/pasi-scorereported in points (0-72 scale), or percent change from baseline as recorded with each finding1 finding from 1 compound
What moved it
How to read these marks1 finding · 1 compound · 1 null · by grade
| Compound | Direction | Findings | Best grade |
|---|---|---|---|
| melatonin | no effect | 1 | Grade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers. |
Every finding here is a null result.
Measured, no effect detected
1 finding
melatonin — no detected effect on
LikelyGrade B, Likely. Human evidence with one recorded weakness, or capped at B by its design or by unread numbers.FindingNull result“Although the PASI score in the melatonin and rosuvastatin groups compared with placebo decreased, the changes were not significant.”
Quoted verbatim from Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.. - Study
- RCT
- Dose
- melatonin cream 5.0% (w/w) applied twice a day
- Population
- adults with mild-to-moderate plaque psoriasis; melatonin cream 5% w/w vs placebo cream, applied twice daily for 8 weeks
Efficacy and safety of topical rosuvastatin & melatonin vs. placebo in patients with mild to moderate plaque psoriasis: A preliminary randomized double-blinded clinical trial.2024PMID:38563131Permalink
How it is measured
Psoriasis Area and Severity Index (PASI), a clinician-scored composite of psoriasis extent and severity across four body regions ranging 0 to 72, reported as the change from baseline to a stated treatment endpoint. Whether the change is reported as an absolute point difference or as a percentage decrease from baseline is recorded with each finding and is not optional — the two are different reported quantities computed from the same underlying instrument.
Measured, not recorded
- Subject
- psoriasis area and severity index (pasi) score
- Measurements
- 1 measurement
- Recorded as a finding
- No
Show what was measured
Psoriasis Area and Severity Index (PASI) score
decreases, PASI score reduced from mean 21.57 to 10.77 with FAE after 16 weeks, unchanged with placebo
Not recorded as a finding: this platform holds no node for the endpoint
Altmeyer et al. 16 reported a reduction of PASI score from a mean of 21·57 at baseline to 10·77 after 16 weeks of FAE treatment, whereas in the placebo group it remained the same (P < 0·001).
PMID:27087044 · one of two readings recorded this
Sources cited
1 paper
- Subject
- psoriasis area and severity index (pasi) score
- Findings
- 1
- Papers
- 1